This HTML5 document contains 72 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n23http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00632/identifier/pharmgkb/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00632/identifier/wikipedia/
n10http://linked.opendata.cz/resource/mesh/concept/
n19http://linked.opendata.cz/resource/drugbank/dosage/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00632/identifier/pubchem-compound/
n4http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB00632/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00632/identifier/drugbank/
n21http://linked.opendata.cz/resource/drugbank/patent/
n25http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n24http://linked.opendata.cz/resource/drugbank/medicinal-product/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00632/identifier/national-drug-code-directory/
n5http://linked.opendata.cz/ontology/drugbank/
n9http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n14http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00632/identifier/chemspider/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00632/identifier/chebi/
n15http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00632
rdf:type
n5:Drug
n5:description
Docosanol is a drug used for topical treatment for recurrent herpes simplex labialis episodes (episodes of cold sores or fever blisters). A saturated 22-carbon aliphatic alcohol, docosanol exhibits antiviral activity against many lipid enveloped viruses including herpes simplex virus (HSV). Docosanol inhibits fusion between the plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication.
n5:dosage
n19:271B5C2A-363D-11E5-9242-09173F13E4C5 n19:271B5C2B-363D-11E5-9242-09173F13E4C5
n5:group
approved investigational
n5:indication
For the topical treatment of recurrent oral-facial herpes simplex episodes (cold sores or fever blisters).
n5:manufacturer
n23:271B5C28-363D-11E5-9242-09173F13E4C5
owl:sameAs
n4:DB00632 n25:DB00632
dcterms:title
Docosanol
adms:identifier
n12:12620 n16:46508049 n17:0135-0200-01 n18:DB00632 n20:31000 n22:12100 n26:PA164749211 n27:Docosanol
n5:mechanismOfAction
Docosanol works by inhibiting fusion between the human cell plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication. Unlike other cold-sore antivirals, docosanol does not act directly on the virus, and as such it is unlikely it will produce drug resistant mutants of HSV.
n5:packager
n23:271B5C27-363D-11E5-9242-09173F13E4C5
n5:patent
n21:2156063 n21:5534554 n21:4874794 n21:2421026
n5:synonym
Abreva Behenyl alcohol Behenic alcohol Tadenan Docosyl alcohol N-Docosanol 1-Docosanol Docosanol Docosan-1-ol
n5:toxicity
Symptoms of overdose include headache, abdominal pain, increased serum lipase, nausea, dyspepsia, dizziness, and hyperbilirubinemia.
n7:hasAHFSCode
n8:84-04-06
n9:hasConcept
n10:M0054012
foaf:page
n14:docosanol.html
n5:IUPAC-Name
n6:271B5C30-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B5C36-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B5C35-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5C32-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5C33-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B5C34-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5C2E-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5C47-363D-11E5-9242-09173F13E4C5 n6:271B5C2F-363D-11E5-9242-09173F13E4C5 n6:271B5C2C-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5C2D-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n15:D06BB11
n5:H-Bond-Acceptor-Count
n6:271B5C3C-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5C3D-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B5C37-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5C38-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5C3A-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5C39-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5C3B-363D-11E5-9242-09173F13E4C5
n5:absorption
Topical absorption has been shown to be minimal under conditions reflecting normal clinical use.
n5:affectedOrganism
Herpes simplex virus
n5:casRegistryNumber
30303-65-2
n5:category
n5:containedIn
n24:271B5C29-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B5C42-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5C44-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5C45-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B5C46-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5C41-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5C40-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5C43-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5C31-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B5C3E-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5C3F-363D-11E5-9242-09173F13E4C5